Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Celator's proprietary technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations, incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. Acquired by Jazz Pharmaceuticals in 2016.